Transparencies About Drug Failures May Accelerate Research

Posted December 13, 2018

A recent opinion piece published in Nature argues for transparency and open discussion when evaluating the reasons behind drug failures in clinical trials for Alzheimer’s disease. The piece includes a link for recommended guidelines for clinical trial design as well as potential data-sharing initiatives. The goal of the editorial is to promote an open discussion of the learning opportunities that are hidden within each failure.